AI Firm Valinor Secures $13M to Revolutionize Clinical Trials
December 16, 2025, 4:57 pm
Location: United States, Utah, Salt Lake City
Employees: 11-50
Founded date: 1986
Valinor, a San Francisco-based AI company, just raised $13 million in seed funding. The company aims to drastically improve clinical trial success rates. It uses AI to predict patient response to drugs *before* trials begin. This “response-first” approach focuses on matching patient biology with treatment outcomes. Traditional drug development faces high failure rates. Valinor’s technology identifies responders early. It also uncovers new biological markers. This reduces costs and accelerates drug delivery. The funding will expand datasets and the team. Investors include CRV and Harpoon Ventures. Valinor’s platform goes beyond simple “yes/no” predictions. It reveals underlying biology linked to positive responses. This allows for refined patient selection. It also opens doors to new drug applications. The pharmaceutical industry needs innovation. Valinor offers a data-driven solution to a costly problem. The company’s focus on matched multi-omic data is key. This differentiates it from competitors. Expect faster, cheaper, and more effective drug development. Valinor’s technology could reshape the future of medicine. It addresses a critical bottleneck in bringing life-saving treatments to patients. The company’s success hinges on its ability to scale its data and refine its AI models. This funding round is a significant step forward. It validates Valinor’s innovative approach.
Valinor received $13 million in seed funding. The round was led by CRV and Harpoon Ventures. Other investors participated. This includes Amino Collective and Pelion Venture Partners. Angel investors also contributed. Joshua Pacini founded and leads Valinor as CEO.
The company focuses on AI-driven drug development. It aims to predict clinical trial outcomes. Traditional trials are expensive and often fail. Valinor’s approach reduces this risk. It uses machine learning and proprietary datasets.
Valinor’s core technology is unique. It analyzes matched multi-omic data. This links patient biology to treatment results. This “response-first” strategy is crucial. It identifies patients most likely to benefit.
The platform doesn’t just predict success or failure. It reveals *why* a drug works for some. This unlocks new possibilities. Drug developers can refine target populations. They can also explore new drug applications.
The funding will fuel expansion. Valinor will grow its datasets. It will also hire more staff. The team is based in San Francisco. The goal is to accelerate drug breakthroughs. This benefits patients and the pharmaceutical industry.
Valinor’s technology addresses a major industry challenge. Clinical trial failures are common. They cost billions of dollars annually. AI offers a solution. It can analyze complex data more efficiently.
The company’s focus on data quality is vital. Matched datasets are essential for accurate predictions. This differentiates Valinor from competitors. Many rely on public or synthetic data.
Valinor’s platform has broad applications. It can be used across therapeutic areas. It also works with various drug modalities. This makes it a versatile tool for drug developers.
The investment signals confidence in Valinor’s vision. It validates the potential of AI in drug discovery. Expect further innovation from this company. It is poised to disrupt the pharmaceutical landscape. The future of clinical trials is data-driven. Valinor is leading the charge.
Valinor received $13 million in seed funding. The round was led by CRV and Harpoon Ventures. Other investors participated. This includes Amino Collective and Pelion Venture Partners. Angel investors also contributed. Joshua Pacini founded and leads Valinor as CEO.
The company focuses on AI-driven drug development. It aims to predict clinical trial outcomes. Traditional trials are expensive and often fail. Valinor’s approach reduces this risk. It uses machine learning and proprietary datasets.
Valinor’s core technology is unique. It analyzes matched multi-omic data. This links patient biology to treatment results. This “response-first” strategy is crucial. It identifies patients most likely to benefit.
The platform doesn’t just predict success or failure. It reveals *why* a drug works for some. This unlocks new possibilities. Drug developers can refine target populations. They can also explore new drug applications.
The funding will fuel expansion. Valinor will grow its datasets. It will also hire more staff. The team is based in San Francisco. The goal is to accelerate drug breakthroughs. This benefits patients and the pharmaceutical industry.
Valinor’s technology addresses a major industry challenge. Clinical trial failures are common. They cost billions of dollars annually. AI offers a solution. It can analyze complex data more efficiently.
The company’s focus on data quality is vital. Matched datasets are essential for accurate predictions. This differentiates Valinor from competitors. Many rely on public or synthetic data.
Valinor’s platform has broad applications. It can be used across therapeutic areas. It also works with various drug modalities. This makes it a versatile tool for drug developers.
The investment signals confidence in Valinor’s vision. It validates the potential of AI in drug discovery. Expect further innovation from this company. It is poised to disrupt the pharmaceutical landscape. The future of clinical trials is data-driven. Valinor is leading the charge.